06.11.2022 08:00 AM CET
Event Host
Paul Craddy, Graham Foxon, Victoria Snell, Charlie Hewitt & Lauren Boland
Event Description

Remap Consulting will join global healthcare leaders, in-person and virtually, as they convene at ISPOR Europe 2022, the leading global conference for health economics and outcomes research (HEOR), 6-9 November for discussion and dissemination of the latest trends in healthcare.

You can find Remap Consulting at booth X2-403.

Remap will be presenting on the below six pieces of research:

  • Does NICE’S STA Process Effectively Reward the Value of Double-Branded Oncology Combinations, When Compared to Oncology Monotherapies?
  • Comparing and Contrasting Early Access Opportunities across the EU4 and UK
  • Could Netflix-Based Subscription Models Tackle the Shrinking Antibiotic Pipeline?
  • Is International Reference Pricing Applied Consistently at Pharmaceutical Price Re-Evaluation for Retail and Speciality Products.
  • Do Manufacturers Still See Value in Submitting Evidence for a NICE Appraisal in England? Comparing and Contrasting Terminated Appraisals Between Oncology and Non-Oncology and Monotherapies and Combination Products.
  • Changing Landscape of Orphan Drug Reimbursement – Evidence from EU-4 and England

If you would like to arrange a meeting to discuss how Remap can support your Market Access, Pricing and Reimbursement challenges, please click the button below.

Arrange a meeting

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.